Diagnosis

What are the most important prognostic factors to consider in AML?

Dr. Desai takes a brief look at the important prognostic factors to consider in your patients with AML.

Published on December 5, 2018 in Diagnosis

Begin

How likely is it for patients with MDS to transform to AML?

Dr. Park discusses the factors that influence whether a patient's MDS will transform to AML, and how to identify those factors in your patient.

Published on November 7, 2018 in Diagnosis

Begin

Alexander Perl, MD

What are the practical issues in FLT3 testing as it relates to PCR vs. NGS?

Dr. Perl compares and contrasts polymerase chain reaction testing vs. next-generation sequencing at the time of initial diagnosis of AML.

Published on October 10, 2018 in Diagnosis

Begin

Jay L. Patel, MD

What are the latest guidelines for molecular testing in AML?

Dr. Patel briefly summarizes recent changes to the NCCN Guidelines for molecular testing and evaluation of AML.

Published on July 24, 2018 in Diagnosis

Begin

Hetty E. Carraway, MD

Do I need to re-test patients at relapse who had an IDH mutation at diagnosis?

Dr. Carraway discusses whether it should be standard practice to re-test patients at relapse if testing at initial diagnosis revealed an IDH mutation.

Published on May 2, 2018 in Diagnosis

Begin

Joseph D. Khoury, MD

53-year-old woman presenting with severe fatigue and bruising

Hematopathologist Dr. Khoury presents a case snapshot showing the complexities of diagnosing AML, and describes the importance of morphology, flow cytometry, cytogenetics, and molecular diagnostics.

Published on March 21, 2018 in Diagnosis

Begin

Elli Papaemmanuil, PhD

Molecular Abnormalities in AML

Dr. Papaemmanuil explains the role of molecular abnormalities in AML oncogenesis, including mutations in DNMT, IDH1/2, and FLT3. In addition, learn how we can begin to interpret and translate these molecular characterizations into clinical practice. Get started now!

Published on March 21, 2018 in Diagnosis

Begin

Joseph D. Khoury, MD

The hematopathologist's role in the diagnosis of AML

Dr. Khoury describes the hematopathologist's investigative toolkit - including morphology, flow cytometry, cytogenetics, and molecular diagnostics - in navigating the complexities of diagnosing AML.

Published on December 26, 2017 in Diagnosis

Begin

Naval Daver, MD

Recommended baseline cytogenetic molecular & immune profiling workup in newly diagnosed AML patients

Dr. Naval Daver discusses the recommended baseline cytogenetic molecular and immune profiling workup for a patient with newly diagnosed acute myeloid leukemia.

Published on May 31, 2017 in Diagnosis

Begin

Brian Druker, MD

Is molecular testing standard/routine for patients diagnosed with AML in the community setting?

Dr. Druker discusses whether routine molecular testing should be a part of the standard analysis of patients with AML in the community setting.

Published on May 31, 2017 in Diagnosis

Begin